Spyre Therapeutics (SYRE) Accumulated Expenses (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Accumulated Expenses data on file, last reported at $29.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 34.81% year-over-year to $29.2 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 34.81% YoY), and the FY2025 full-year result was $26.9 million, down 2.76% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $29.2 million, up from $26.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $29.2 million in Q1 2026 and bottomed at $2.4 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $15.9 million (2023), against an average of $17.5 million.
• The widest annual swing landed in 2022, when Accumulated Expenses jumped 353.12%; it then sank 80.01% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $12.8 million in 2022, then advanced by 2.11% to $13.1 million in 2023, then soared by 111.41% to $27.7 million in 2024, then decreased by 2.76% to $26.9 million in 2025, then grew by 8.21% to $29.2 million in 2026.
• The last three Accumulated Expenses figures came in at $29.2 million (Q1 2026), $26.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.

Peer Comparison